Quantcast

Latest Percutaneous coronary intervention Stories

2014-03-25 16:25:35

DUBLIN, Mar. 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/k8gx4n/china ) has announced the addition of the "Concise Analysis of the International Interventional Cardiovascular Device Industry" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning...

2014-03-24 20:23:53

Second Generation drug coated balloon designed to address both acute and long-term outcomes PLEASANTON Calif. and SINGAPORE, March 24, 2014 /PRNewswire/ -- TriReme Medical LLC, a subsidiary of Singapore based QT Vascular Ltd. announced today that the first three patients were enrolled in a clinical study of its unique drug-coated Chocolate® PTA balloon. Dr. Andrew Holden, co-Principal Investigator of the study, performed these procedures at Auckland City Hospital, in Auckland, New...

2014-03-13 23:29:08

Program envisions enabling remote robotic-assisted PCI for patients in rural areas. Waltham, MA (PRWEB) March 13, 2014 Corindus Vascular Robotics (http://www.corindus.com/), a leading developer of precision vascular robotics and provider of the CorPath Vascular Robotic System, today announced a partnership with Sanford Health and The Leona M. and Harry B. Helmsley Charitable Trust to launch a feasibility investigation for a remote robotics program. For many patients living in rural areas,...

2014-03-12 20:24:11

Conference Call and Webcast on March 13 at 8:30 a.m. EDT BASKING RIDGE, N.J., March 12, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. A conference call and webcast to discuss the results will be held March 13 at 8:30 a.m. EDT. David J....

2014-03-10 08:29:26

Enrollment in the Phase 3 REGULATE-PCI Trial is Ongoing for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention BASKING RIDGE, N.J., March 10, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration (FDA) has designated REG1 for anticoagulant therapy to be used in patients with coronary...

2014-03-06 12:26:53

Increasing Presence of Domestic Competitors Will Undercut Prices Set by Multinational Companies, According to Findings from Decision Resources Group BURLINGTON, Mass., March 6, 2014 /PRNewswire/ -- Decision Resources Group finds that growth in the Chinese market for interventional cardiology (IC) devices has slowed dramatically compared to previous years due to increasing competition from domestic competitors. Smaller local competitors are looking to enter the drug-eluting stent...

2014-03-06 08:30:36

BASKING RIDGE, N.J., March 6, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will hold a conference call and live audio webcast on Thursday, March 13, at 8:30 a.m. EDT to discuss its year-end and fourth quarter 2013 financial results. Interested participants and investors may access the...

2014-02-13 12:27:49

LONDON, Feb. 13, 2014 PRNewswire/ -- Reportbuyer.com just published a new market research report:China Interventional Cardiovascular Device Industry Report, 2013-2015 With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People's Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients...

2014-02-13 08:30:31

REG2 Extends Regado's Next-Generation Anticoagulation Therapy Franchise as Phase 3 REGULATE-PCI Clinical Trial of REG1 Advances BASKING RIDGE, N.J., Feb. 13, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration (FDA) has accepted the company's...

2014-02-12 08:28:36

New Patent Extends Coverage to Peptide- and Protein-Based Control Agents BASKING RIDGE, N.J., Feb. 12, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Patent and Trademark Office (USPTO) has issued an important patent that expands protection of Regado's core technology platform...


Latest Percutaneous coronary intervention Reference Libraries

Coronary Angiography
2013-07-29 11:05:01

A coronary angiography, also known as a coronary catheterization, is a procedure that gives both visual and tactical access to coronary circulation and blood filled chambers of the heart for both diagnostic and interventional purposes. It is one of many diagnostic tests used in cardiology. More specifically, coronary catheterization recognizes occlusion, stenosis, thrombosis or aneurismal enlargement of the walls of the coronary arteries; heart chamber size; heart muscle contraction...

More Articles (1 articles) »
Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.